ZONTIVITY (Merck Sharp & Dohme Corp.)
Welcome to the PulseAid listing for the ZONTIVITY drug offered from Merck Sharp & Dohme Corp.. This Protease-activated Receptor-1 Antagonist [EPC],Protease-activated Receptor-1 Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Merck Sharp & Dohme Corp. |
NON-PROPRIETARY NAME: | vorapaxar |
SUBSTANCE NAME: | VORAPAXAR SULFATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Protease-activated Receptor-1 Antagonist [EPC],Protease-activated Receptor-1 Antagonists [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-05-08 |
END MARKETING DATE: | 0000-00-00 |
ZONTIVITY HUMAN PRESCRIPTION DRUG Details:
Item Description | ZONTIVITY from Merck Sharp & Dohme Corp. |
LABELER NAME: | Merck Sharp & Dohme Corp. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 2.08(mg/1) |
START MARKETING DATE: | 2014-05-08 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0006-0351_ae634203-7414-4955-95ff-fa16cf025ab2 |
PRODUCT NDC: | 0006-0351 |
APPLICATION NUMBER: | NDA204886 |
Other VORAPAXAR SULFATE Pharmaceutical Manufacturers / Labelers: